Nyakas, Marta
Fleten, Karianne Giller
Haugen, Mads Haugland
Engedal, Nikolai
Sveen, Christina
Farstad, Inger Nina
Flørenes, Vivi Ann
Prasmickaite, Lina
Mælandsmo, Gunhild Mari
Seip, Kotryna
Funding for this research was provided by:
Bodil and Magnes Foundation
Helse Sør-Øst RHF (2019081, 2021088, 2016117)
Kreftforeningen (190257)
Article History
Received: 29 July 2021
Accepted: 14 March 2022
First Online: 24 March 2022
Competing interests
: Marta Nyakas is a PI in the BGBIL006 study (NCT02872259): <i>BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma</i>. Oslo, Norway. In addition, she has honorarium for Lectures and Expert meetings for BMS, MSD, Novartis and Pierre-Fabre. The other co-authors declare no competing interests.